Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
By A. Gotto, E. Whitney, E. Stein, D. Shapiro, M. Clearfield, Stephen E. Weis, Jesse Jou, A. Langendorfer, P. Beere, D. Watson and 2 more. Circulation, 2000
635 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Surgery
View Paper: https://www.semanticscholar.org/paper/026e6bc09bc22d58146ea5324e5cad2962527ed8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
- P. Ridker
- Ralph B. D’Agostino
- Michael J. Pencina
- Ramachandran S. Vasan
- R. Goldberg
- Lisa Sullivan
- N. Rifai
- Peter Libby
In Epidemiology
- P. Ridker
- N. Rifai
- Michael J. Pencina
- R. Goldberg
- Peter W. F. Wilson
- Nancy R. Cook
- Ralph B. D’Agostino
- Peter Libby
In Surgery
- P. Ridker
- N. Rifai
- R. Goldberg
- Michael J. Pencina
- Nancy R. Cook
- G. Bradwin
- Ralph B. D’Agostino
- J. Buring
Citations in the corpus
- Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. (2005, background): “However, in the Air Force Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), a randomized trial of lovastatin, the levels of apolipoprotein B100 when participants were receiving treatment and the ratio of apolipoprotein B100 to apolipoprotein A-I were better predictors of future cardi”
- Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. (2007, background): “Another advantage of the apolipoproteins is that they are better predictors of CHD risk of patients who are taking lipid-lowering treatment (vs traditional lipid measures).(32) Also, the INTERHEART study has clearly established the strong association of the apo B:apo A-I ratio with the incidence of ”
- Statins and cancer prevention (2005, background): “However, the efficacy of statins in reducing cardiac events seems to exceed the degree of cholesterol reduction and extends to patients with normal cholesterol level”
- Lipoprotein Management in Patients With Cardiometabolic Risk (2008, background): “As with non-HDL cholesterol and NMR-based measurements of LDL particle number, in several epidemiological studies and in post hoc analyses of clinical trials, apoB has been found to be a better predictor of CVD risk than LDL cholesterol (41,42), particularly the ont rea tment LDL choles te ro l l ev”